These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36553542)

  • 1. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
    Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsa_circ_0000497 and hsa_circ_0000918 contributed to peritoneal metastasis of ovarian cancer via ascites.
    Luo N; Sulaiman Z; Wang C; Ding J; Chen Y; Liu B; Cheng Z; Liu S
    J Transl Med; 2022 May; 20(1):201. PubMed ID: 35538537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Voyage of Ovarian Cancer Cells in Ascites with the Assistance of Various Cellular Components.
    Uno K; Iyoshi S; Yoshihara M; Kitami K; Mogi K; Fujimoto H; Sugiyama M; Koya Y; Yamakita Y; Nawa A; Kanayama T; Tomita H; Enomoto A; Kajiyama H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylation model predicts prognosis of patients and affects immune microenvironment infiltration in epithelial ovarian carcinoma.
    Wang X; Li X; Wei L; Yu Y; Hazaisihan Y; Tao L; Jia W
    J Ovarian Res; 2024 Jul; 17(1):150. PubMed ID: 39030559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
    Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
    BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between Treg cells and tumor-associated macrophages in the tumor microenvironment of epithelial ovarian cancer.
    Zhu Q; Wu X; Wu Y; Wang X
    Oncol Rep; 2016 Dec; 36(6):3472-3478. PubMed ID: 27748885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
    Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
    Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
    Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.
    Harrington BS; Kamdar R; Ning F; Korrapati S; Caminear MW; Hernandez LF; Butcher D; Edmondson EF; Traficante N; Hendley J; ; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Nag ML; Mazan-Mamczarz K; House CD; Hooper JD; Annunziata CM
    J Exp Clin Cancer Res; 2023 Oct; 42(1):270. PubMed ID: 37858159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
    da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased peritoneal TGF-β1 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer.
    Maas RJA; Hoogstad-van Evert JS; Hagemans IM; Brummelman J; van Ens D; de Jonge PKJD; Hooijmaijers L; Mahajan S; van der Waart AB; Hermans CKJC; de Klein J; Woestenenk R; van Herwaarden AE; Schaap NPM; Rezaeifard S; Tauriello DVF; Zusterzeel PLM; Ottevanger N; Jansen JH; Hobo W; Dolstra H
    Front Immunol; 2024; 15():1448041. PubMed ID: 39376560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer.
    Shao W; Lin Z; Xiahou Z; Zhao F; Xu J; Liu X; Cai P
    Front Immunol; 2024; 15():1438198. PubMed ID: 39136009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
    BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of tumour microenvironment reprogramming reveals invasion in epithelial ovarian carcinoma.
    Zhang Y; Sun S; Qi Y; Dai Y; Hao Y; Xin M; Xu R; Chen H; Wu X; Liu Q; Kong C; Zhang G; Wang P; Guo Q
    J Ovarian Res; 2023 Oct; 16(1):200. PubMed ID: 37817210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIPE2 acts as a tumor suppressor and correlates with tumor microenvironment immunity in epithelial ovarian cancer.
    Xu S; Gao X; Qiu J; Hong F; Gao F; Wang X; Zhang S
    Aging (Albany NY); 2023 Feb; 15(4):1052-1073. PubMed ID: 36801818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites.
    Zhang L; Strange M; Elishaev E; Zaidi S; Modugno F; Radolec M; Edwards RP; Finn OJ; Vlad AM
    Front Immunol; 2024; 15():1379175. PubMed ID: 39086481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.